134 related articles for article (PubMed ID: 9864966)
1. Effects of interferon-alpha and gamma on development of LAK activity from mononuclear cells in breast cancer patients.
Kamamura Y; Takahashi K; Komaki K; Monden Y
J Med Invest; 1998 Aug; 45(1-4):71-5. PubMed ID: 9864966
[TBL] [Abstract][Full Text] [Related]
2. Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma.
Ellis TM; McKenzie RS; Simms PE; Helfrich BA; Fisher RI
J Immunol; 1989 Dec; 143(12):4282-6. PubMed ID: 2512355
[TBL] [Abstract][Full Text] [Related]
3. Effect of TNF-alpha and IFN-alpha on the proliferation and cytotoxicity of lymphokine-activated killer cells in patients with bladder cancer.
Wang Z; Cheng Y; Zheng R; Qin D; Liu G
Chin Med J (Engl); 1997 Mar; 110(3):180-3. PubMed ID: 9594335
[TBL] [Abstract][Full Text] [Related]
4. Decrease of lymphokine (interleukin-2)-activated killer activity in peripheral blood after administration of natural interferon-gamma.
Yanagawa H; Sone S; Okubo A; Fukuta K; Nishioka Y; Ogura T
Jpn J Clin Oncol; 1990 Dec; 20(4):356-63. PubMed ID: 2126575
[TBL] [Abstract][Full Text] [Related]
5. Influence of various cytokines on the induction of lymphokine-activated killer cells.
Bergmann L; Weidmann E; Bungert B; Hechler P; Mitrou PS
Nat Immun Cell Growth Regul; 1990; 9(4):265-73. PubMed ID: 2120581
[TBL] [Abstract][Full Text] [Related]
6. On the relative roles of interleukin-2 and interleukin-10 in the generation of lymphokine-activated killer cell activity.
Spagnoli GC; Juretic A; Schultz-Thater E; Dellabona P; Filgueira L; Hörig H; Zuber M; Garotta G; Heberer M
Cell Immunol; 1993 Feb; 146(2):391-405. PubMed ID: 8174177
[TBL] [Abstract][Full Text] [Related]
7. [Augmentation of cytotoxic activity by combination with interleukin 2 and interferon gamma].
Tsunoda T; Tanimura H; Yamaue H; Tani M; Iwahashi M
Nihon Gan Chiryo Gakkai Shi; 1990 Jun; 25(6):1110-8. PubMed ID: 2118938
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY
J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887
[TBL] [Abstract][Full Text] [Related]
9. Augmentation of cytotoxic activity by combination with interleukin 2 and interferon gamma.
Tsunoda T; Tanimura H; Yamaue H; Iwahashi M; Tani M; Tamai M; Noguchi K; Arii K; Hotta T
Nihon Geka Hokan; 1991 Nov; 60(6):396-405. PubMed ID: 1820012
[TBL] [Abstract][Full Text] [Related]
10. Protection of cultured human monocytes from lymphokine-activated killer-mediated lysis by IFN-gamma.
Blanchard DK; Djeu JY
J Immunol; 1988 Dec; 141(11):4067-73. PubMed ID: 2460557
[TBL] [Abstract][Full Text] [Related]
11. Generation of human lymphokine-activated killer cells following an IL-2 pulse in elderly cancer patients.
Provinciali M; Di Stefano G; Stronati S; Fabris N
Cytokine; 1998 Feb; 10(2):132-9. PubMed ID: 9512903
[TBL] [Abstract][Full Text] [Related]
12. [The role of interferons in neuroblastoma. 2: Immunomodulatory effects].
Handgretinger R; Bruchelt G; Daurer B; Lang P; Dopfer R; Reisfeld RA; Treuner J; Niethammer D
Klin Padiatr; 1990; 202(4):206-11. PubMed ID: 2118581
[TBL] [Abstract][Full Text] [Related]
13. Antiestrogens sensitize human ovarian and lung carcinomas for lysis by autologous killer cells.
Baral E; Nagy E; Krepart GV; Lotocki RJ; Unruh HW; Berczi I
Anticancer Res; 2000; 20(3B):2027-31. PubMed ID: 10928146
[TBL] [Abstract][Full Text] [Related]
14. Differential effect of interleukin 10 on interleukin 12- and interleukin 2-mediated killer induction from blood mononuclear cells.
Pai K; Yanagawa H; Takauchi E; Suzuki Y; Hanibuchi M; Parajuli P; Sone S
Oncol Res; 1998; 10(6):295-300. PubMed ID: 9848100
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of lymphokine-activated killer cell induction using anti-CD25 and anti-CTLA-4 monoclonal antibodies.
Okita R; Yamaguchi Y; Emi A; Matsuura K; Toge T
Oncol Rep; 2007 Jun; 17(6):1429-35. PubMed ID: 17487401
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of IL-18 receptor in cancer patients: its clinical significance.
Kobashi K; Iwagaki H; Yoshino T; Morimoto Y; Kohka H; Kodama M; Nishibori M; Akagi T; Tanaka N
Anticancer Res; 2001; 21(5):3285-93. PubMed ID: 11848485
[TBL] [Abstract][Full Text] [Related]
17. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
18. Enhanced in vitro and in vivo cytotoxicity of umbilical cord blood cells against human breast cancer following activation with IL-15 and colony stimulating factors.
Lovgren TR; Tarantolo SR; Evans C; Kuszynski CA; Joshi SS
In Vivo; 2002; 16(6):541-50. PubMed ID: 12494899
[TBL] [Abstract][Full Text] [Related]
19. IL-2-activated cord blood mononuclear cells.
Derzic S; Slone V; Sender L
Cytotherapy; 2005; 7(5):408-16. PubMed ID: 16236630
[TBL] [Abstract][Full Text] [Related]
20. Retaliation against tumor cells showing aberrant HLA expression using lymphokine activated killer-derived T cells.
Falk CS; Noessner E; Weiss EH; Schendel DJ
Cancer Res; 2002 Jan; 62(2):480-7. PubMed ID: 11809699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
